# Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

> **NCT06250504** · PHASE3 · UNKNOWN · sponsor: **Africa Health Research Institute** · enrollment: 2000 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** APRETUDE (cabotegravir) 600 mg\3 mL
- **DRUG:** DAPIRING (Dapivirine) 25mg Vaginal Ring
- **DRUG:** tenofovir disoproxil and emtricitabine
- **DRUG:** Tenofovir Disoproxil, Lamuvidine and Dolutegravir

## Key facts

- **NCT ID:** NCT06250504
- **Lead sponsor:** Africa Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-27
- **Primary completion:** 2025-07
- **Final completion:** 2026-03
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06250504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06250504, "Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06250504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*